Virax Biolabs Group (VRAX) Competitors $0.86 +0.01 (+0.59%) As of 07/3/2025 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. SNSE, XFOR, SNPX, CSCI, PHXM, BCDA, NLSP, GLYC, LSB, and ADXNShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Sensei Biotherapeutics (SNSE), X4 Pharmaceuticals (XFOR), Synaptogenix (SNPX), COSCIENS Biopharma (CSCI), PHAXIAM Therapeutics (PHXM), BioCardia (BCDA), NLS Pharmaceutics (NLSP), GlycoMimetics (GLYC), LakeShore Biopharma (LSB), and Addex Therapeutics (ADXN). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Its Competitors Sensei Biotherapeutics X4 Pharmaceuticals Synaptogenix COSCIENS Biopharma PHAXIAM Therapeutics BioCardia NLS Pharmaceutics GlycoMimetics LakeShore Biopharma Addex Therapeutics Sensei Biotherapeutics (NASDAQ:SNSE) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation. Does the media favor SNSE or VRAX? In the previous week, Sensei Biotherapeutics' average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score. Company Overall Sentiment Sensei Biotherapeutics Neutral Virax Biolabs Group Neutral Is SNSE or VRAX more profitable? Virax Biolabs Group's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sensei BiotherapeuticsN/A -66.72% -57.10% Virax Biolabs Group N/A N/A N/A Which has more risk and volatility, SNSE or VRAX? Sensei Biotherapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Do analysts prefer SNSE or VRAX? Sensei Biotherapeutics currently has a consensus price target of $90.00, indicating a potential upside of 891.74%. Virax Biolabs Group has a consensus price target of $3.00, indicating a potential upside of 246.82%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Sensei Biotherapeutics is more favorable than Virax Biolabs Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in SNSE or VRAX? 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 23.2% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger earnings and valuation, SNSE or VRAX? Virax Biolabs Group has higher revenue and earnings than Sensei Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSensei BiotherapeuticsN/AN/A-$30.16M-$23.00-0.39Virax Biolabs Group$10K375.41-$6.06MN/AN/A SummaryVirax Biolabs Group beats Sensei Biotherapeutics on 6 of the 11 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.69M$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E RatioN/A21.5627.6520.23Price / Sales375.41283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book0.697.538.035.65Net Income-$6.06M-$55.14M$3.18B$249.15M7 Day Performance10.90%4.61%2.93%3.28%1 Month Performance-11.60%0.90%1.72%3.95%1 Year Performance-29.10%5.40%34.39%20.98% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group2.854 of 5 stars$0.87+0.6%$3.00+246.8%-29.1%$3.69M$10K0.005SNSESensei Biotherapeutics4.1881 of 5 stars$8.75+2.0%$90.00+928.6%-27.1%$11.03MN/A-0.3840Gap DownXFORX4 Pharmaceuticals4.3383 of 5 stars$1.90-0.3%$72.33+3,717.1%-88.1%$10.97M$2.56M0.8880News CoverageSNPXSynaptogenix1.1488 of 5 stars$7.85+29.8%$14.00+78.3%+106.8%$10.91MN/A-0.784Gap DownHigh Trading VolumeCSCICOSCIENS BiopharmaN/A$3.42+0.6%N/AN/A$10.77M$9.59M-0.5920PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049BCDABioCardia3.9871 of 5 stars$2.04+4.4%$25.00+1,128.5%-29.0%$10.54M$60K-0.8740News CoveragePositive NewsInsider TradeNLSPNLS PharmaceuticsN/A$2.88-0.7%N/A+1,191.0%$10.37MN/A0.006News CoverageAnalyst UpgradeGap UpGLYCGlycoMimetics1.1469 of 5 stars$0.16-6.6%N/A-99.4%$10.00M$10K-0.3450High Trading VolumeLSBLakeShore Biopharma0.3358 of 5 stars$1.06+3.4%N/AN/A$9.82M$80.82M0.00773Positive NewsGap UpADXNAddex Therapeutics2.701 of 5 stars$9.21-2.2%$30.00+225.9%+7.0%$9.76M$460K-27.0730High Trading Volume Related Companies and Tools Related Companies Sensei Biotherapeutics Competitors X4 Pharmaceuticals Competitors Synaptogenix Competitors COSCIENS Biopharma Competitors PHAXIAM Therapeutics Competitors BioCardia Competitors NLS Pharmaceutics Competitors GlycoMimetics Competitors LakeShore Biopharma Competitors Addex Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
